Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
None
Guardado en:
Autores principales: | Yusuke Johira, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Michio Imamura, Kazuhiro Sentani, Naohide Oue, Koji Arihiro, Shintaro Kuroda, Tsuyoshi Kobayashi, Hideki Ohdan, Kazuaki Chayama, Hiroshi Aikata |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Karger Publishers
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/223812ca25cd4aecbe1ae5ead2c18af8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021) -
Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
por: L. V. Bolotina
Publicado: (2020) -
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Atsushi Hiraoka, et al.
Publicado: (2021) -
Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Qiyi Zhang, et al.
Publicado: (2021) -
Unresectable hepatoblastoma: current perspectives
por: Trobaugh-Lotrario AD, et al.
Publicado: (2017)